| Autor: |
Raquel Benedetto, Adriana Vidal Fernandes Massicano, Jefferson Jesus Silva, Cristian Antonio Wieczorek Villas Boas, Jair Mengatti, Elaine Bortoleti de Araújo |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Brazilian Journal of Pharmaceutical Sciences, Vol 53, Iss 4 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2175-9790 |
| DOI: |
10.1590/s2175-97902017000417039 |
| Popis: |
ABSTRACT Scientific innovations in diagnostic methods are important drivers of cancer control and prevention. Noninvasive imaging of the epidermal growth factor receptor (EGFR) in head-and-neck squamous, cell carcinoma and colorectal cancer could be valuable to select patients for EGFR-targeted therapy, as well as to monitor the efficacy and occurrence of resistance to immunotherapy. In order to develop the first Brazilian radioimmunoconjugate for diagnosis, Cetuximab has been conjugated to p-SCN-Bn-DTPA chelator and radiolabeled with Indium-111. The conjugation methodology was optimized using different mAb:DTPA molar ratios, time was then reduced for immunoconjugate preparation, besides the protein recovery’ percentage increased after purification (m = 83.8 ± 0.91 %). The stability of Cetuximab-DTPA at - 20 oC was evaluated for six months, and its integrity was greater than 90% (m =93.9 ± 1.5%, N = 24). The radioimmunoconjugate with specific activity of 185 MBq/mg showed radiochemical purity above 95% (m=96.8 ± 1.31 %, N = 15). We conclude that the radioimmunoconjugate 111In-DTPA-cetuximab is stable and may be applied to the diagnosis of EGFR-positive tumors. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
